The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 964-975

  Montini, Eugenio ^a   Cesana, Daniela ^a,b   Schmidt, Manfred ^c   Sanvito, Francesca ^d   Bartholomae, Cynthia C ^c   Ranzani, Marco ^a,b   Benedicenti, Fabrizio ^a   Sergi, Lucia Sergi ^a   Ambrosi, Alessandro ^b   Ponzoni, Maurilio ^d   Doglioni, Claudio ^b,d   Di Serio, Clelia ^b   Von Kalle, Christof ^c   Naldini, Luigi ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; CDKN2A PROTEIN, MOUSE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENOTOXICITY; HELA CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL GENE THERAPY; TUMOR GENE; ANIMAL; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; METHODOLOGY; MOUSE MUTANT; MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENICITY; RETROVIRUS; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; GAMMARETROVIRUS; GENE THERAPY; GENES, P16; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LENTIVIRUS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; NEOPLASMS, EXPERIMENTAL; TERMINAL REPEAT SEQUENCES;

EID: 65249101260     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37630     Document Type: Article

References (67)

1. von Kalle, C., et al. 2004. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin. Hematol. 41:303-318.
2. Baum, C., et al. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101:2099-2114.
3. Hacein-Bey-Abina, S., et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-256.
4. Ott, M.G., et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12:401-409.
5. Will, E., et al. 2007. Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol. Ther. 15:782-791.
6. Williams, D.A. 2006. Gene therapy advances but struggles to interpret safety data in small animal models. Mol. Ther. 13:1027-1028.
7. Montini, E., et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687-696.
8. Sherr, C.J. 2001. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:731-737.
9. Sherr, C.J. 2004. Principles of tumor suppression. Cell. 116:235-246.
10. Hacein-Bey-Abina, S., et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118:3132-3142.
11. Howe, S.J., et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCIDX1 patients. J. Clin. Invest. 118:3143-3150.
12. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
13. Roberts, M.R., et al. 1998. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J. Immunol. 161:375-384.
14. Hematti, P., et al. 2004. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2:e423.
15. Lewinski, M.K., et al. 2006. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2:e60.
16. Schroder, A.R., et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110:521-529.
17. Wu, X., Li, Y., Crise, B., and Burgess, S.M. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:1749-1751.
18. Zufferey, R., et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880.
19. Lenz, J., et al. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature. 308:467-470.
20. Jonkers, J., and Berns, A. 1996. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta. 1287:29-57.
21. Modlich, U., et al. 2006. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 108:2545-2553.
22. Modlich, U., et al. 2008. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia. 22:1519-1528.
23. Bushman, F., et al. 2005. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3:848-858.
24. De Palma, M., et al. 2005. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 105:2307-2315.
25. Cattoglio, C., et al. 2007. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. 110:1770-1778.
26. Aiuti, A., et al. 2007. Multilineage hematopoietic reconstitution without clonal selection in ADASCID patients treated with stem cell gene therapy. J. Clin. Invest. 117:2233-2240.
27. Deichmann, A., et al. 2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117:2225-2232.
28. Schwarzwaelder, K., et al. 2007. Gammaretrovirusmediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 117:2241-2249.
29. Bushman, F.D. 2007. Retroviral integration and human gene therapy. J. Clin. Invest. 117:2083-2086.
30. Baum, C., et al. 1997. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J. Virol. 71:6323-6331.
31. Schambach, A., et al. 2000. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2:435-445.
32. Lund, A.H., et al. 2002. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat. Genet. 32:160-165.
33. Serrano, M., et al. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:27-37.
34. Schmidt, M., et al. 2007. High-resolution insertionsite analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods. 4:1051-1057.
35. Akagi, K., Suzuki, T., Stephens, R.M., Jenkins, N.A., and Copeland, N.G. 2004. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 32:D523-D527.
36. Hosack, D.A., Dennis, G., Jr., Sherman, B.T., Lane, H.C., and Lempicki, R.A. 2003. Identifying biological themes within lists of genes with EASE. Genome Biol. 4:R70.
37. Kratz, C.P., et al. 2007. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia. 21:1108-1109.
38. Rogaia, D., et al. 1997. The localization of the HRX/ ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner. Cancer Res. 57:799-802.
39. Collier, L.S., Carlson, C.M., Ravimohan, S., Dupuy, A.J., and Largaespada, D.A. 2005. Cancer gene discovery in solid tumours using transposonbased somatic mutagenesis in the mouse. Nature. 436:272-276.
40. Martinez-Glez, V., and Lapunzina, P. 2007. Sotos syndrome is associated with leukemia/lymphoma. Am J. Med. Genet. A. 143A:1244-1245.
41. Wu, X., Luke, B.T., and Burgess, S.M. 2006. Redefining the common insertion site. Virology. 344:292-295.
42. Zychlinski, D., et al. 2008. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16:718-725.
43. Kustikova, O.S., et al. 2007. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood. 109:1897-1907.
44. Hacein-Bey-Abina, S., et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:415-419.
45. Dupuy, A.J., Akagi, K., Largaespada, D.A., Copeland, N.G., and Jenkins, N.A. 2005. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 436:221-226.
46. Modlich, U., et al. 2005. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 105:4235-4246.
47. de Ridder, J., et al. 2007. Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. Bioinformatics. 23:i133-i141.
48. Uren, A.G., et al. 2008. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell. 133:727-741.
49. Celander, D., and Haseltine, W.A. 1984. Tissuespecific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses. Nature. 312:159-162.
50. Ramezani, A., Hawley, T.S., and Hawley, R.G. 2008. Combinatorial incorporation of enhancer blocking components of the chicken {beta}-globin 5'HS4 and human T-cell receptor {alpha}/{delta} BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells. 26:3257-3266.
51. Bokhoven, M., et al. 2009. Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83:283-294.
52. Schambach, A., Galla, M., Maetzig, T., Loew, R., and Baum, C. 2007. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther. 15:1167-1173.
53. Bauer, T.R., Jr., et al. 2008. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat. Med. 14:93-97.
54. Hu, J., et al. 2008. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol. Ther. 16:1617-1623.
55. Izsvak, Z., and Ivics, Z. 2004. Sleeping beauty transposition: biology and applications for molecular therapy. Mol. Ther. 9:147-156.
56. Ryu, B.Y., et al. 2008. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood. 111:1866-1875.
57. Lombardo, A., et al. 2007. Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat. Biotechnol. 25:1298-1306.
58. Bibikova, M., Beumer, K., Trautman, J.K., and Carroll, D. 2003. Enhancing gene targeting with designed zinc finger nucleases. Science. 300:764.
59. Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.L., Mitrophanous, K., and Collins, M. 2003. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21:569-572.
60. Naldini, L., et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263-267.
61. Hadjantonakis, A.K., Gertsenstein, M., Ikawa, M., Okabe, M., and Nagy, A. 1998. Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech. Dev. 76:79-90.
62. Schmidt, M., et al. 2001. A model for the detection of clonality in marked hematopoietic stem cells. Ann. N. Y. Acad. Sci. 938:146-155; discussion 155-146.
63. Schmidt, M., et al. 2005. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 105:2699-2706.
64. Schmidt, M., et al. 2001. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum. Gene Ther. 12:743-749.
65. Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
66. Zhao, S., and Fernald, R.D. 2005. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J. Comput. Biol. 12:1047-1064.
67. Hellemans, J., Mortier, G., De Paepe, A., Speleman, F., and Vandesompele, J. 2007. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8:R19.